{"nct_id":"NCT03861793","title":"A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)","status":"COMPLETED","status_verified_date":"2024-03","start_date":"2019-02-26","start_date_type":"ACTUAL","primary_completion_date":"2023-03-01","primary_completion_date_type":"ACTUAL","completion_date":"2023-03-01","completion_date_type":"ACTUAL","phases":["PHASE1","PHASE2"],"tickers":["MURA"]}